Drug Trial Radar · NCT05737784
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 13, 2023
Primary completion
Apr 1, 2026
Study completion Feb 2028
Sponsor
- Lead sponsor
- Praxis Precision MedicinesIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Conditions
- SCN2A-DEE
- Epilepsy
Interventions
PRAX-222 - Initial DoseDrug
PRAX-222
PRAX-222 - Initial Ascending DosesDrug
Ascending doses of PRAX-222
PRAX-222 - Optional Ascending DosesDrug
Escalation of PRAX-222 dose(s)
PRAX-222 - Fixed DosesDrug
Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
PlaceboProcedure
Placebo procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation)Time frame: Screening (-8 weeks) through up to 92 weeks
- Seizure frequency (Confirmatory Phase)Time frame: 36 to 40 weeks
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Le Bonheur Childrens Hospital
Memphis, Tennessee
Praxis Research Site
São Paulo, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.